Researchers are excited about this new drug, a novel dual agonist showing promising results in early trials for size loss . It acts by targeting both pathways : GLP-1 and GIP, which , when engaged , help influence hunger and improve metabolism . Initial reports suggest noteworthy weight reduction and likely improvements for people dealing with a we